89Zr-TLX250 PET/CT

DRUG2 trials

Sponsors

Nantes University Hospital, Telix Pharmaceuticals (Innovations) Pty Limited

Conditions

Clear Cell Renal Cell CarcinomaHepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)Neuroendocrine Tumors

Phase 3

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

RecruitingNCT06750419

Telix Pharmaceuticals (Innovations) Pty LimitedClear Cell Renal Cell Carcinoma

Start: 2024-11-06End: 2026-06-30Target: 82Updated: 2024-12-27

Unknown Phase

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN

RecruitingNCT06735560

Nantes University HospitalHepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Neuroendocrine Tumors

Start: 2025-11-04End: 2027-08-04Target: 60Updated: 2026-05-13